June 19, 2020
The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development and approval or conditional approval of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species (MUMS). The individual award amount has been increased to a single funding level up to $250,000.
Only animal drug sponsors with Designated MUMS animal drugs or their research partners are eligible to apply. Applicants must also meet other eligibility requirements.
The Minor Use and Minor Species Animal Health Act of 2004 (the MUMS act) provides innovative ways to bring products to market for these small populations and is designed to help veterinary pharmaceutical companies and others overcome the financial roadblocks they face in providing animal drugs for a limited market. Before this legislation, veterinary pharmaceutical companies and others would rarely attempt to bring such drugs to market.
Grants awarded through the MUMS program support the FDA’s continuing mission to assure that safe and effective animal drugs are available for a wide range of species and conditions. MUMS grants have been awarded to support product development for a wide range of indications. They have funded many studies for products to treat fungal and bacterial diseases in various fish species, a few for treatment of cancers in dogs, and some to support development of drugs for horses, pheasants, and goats.
To date, the MUMS grant program has provided more than $4.8 million in support of 61 studies. In May, 2020, the FDA awarded four new grants totaling $615,023 to help fund research to support the approval or conditional approval of new animal drugs intended for minor uses or minor species (MUMS).
The complete FOA is available at https://grants.nih.gov/grants/guide/pa-files/PAR-18-827.html.
For More Information:
Issued by FDA Center for Veterinary Medicine.
For questions, Contact CVM.